Craniofacial Muscles

86 F. Pedrosa Domellöf
References
Ag G, Smith TJ (2008) Recent insights into the pathogenesis and management of thyroid-associated
ophthalmopathy. Curr Opin Endocrinol Diabetes Obes 15:446–452
Ahmadi M, Liu J-X, Brännström T, Andersen PM, Stål P, Pedrosa-Domellöf F (2010) Human
extraocular muscles in amyotrophic lateral sclerosis. Invest Ophthalmol Vis Sci 51:3494–3501
Andersen PM (2006) Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide
dismutase gene. Curr Neurol Neurosci Rep 6:37–46
Andrade FH, Porter JD, Kaminski HJ (2000) Eye muscle sparing by the muscular dystrophies:
lessons to be learned? Microsc Res Tech 48:192–203
Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A et al (2008) Consensus statement of the
European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy.
Eur J Endocrinol 158:273–285
Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ et al (1996) Clinical features of Graves’ ophthalmopathy
in an incidence cohort. Am J Ophthalmol 121:284–290
Boillée S, Van de Velde C, Cleveland DW (2006) ALS: a disease of motor neurons and their nonneuronal
neighbors. Neuron 52:39–59
Bonnemann CG, Modi R, Noguchi S et al (1995) Beta-sarcoglycan (A3b) mutations cause autosomal
recessive muscular dystrophy with loss of the sarcoglycan complex [published erratum
appears in Nat Genet 1996 January; 12 (1). 110]. Nat Genet 11:266–273
Brais B (2003) Oculopharyngeal muscular dystrophy: a late-onset polyalanine disease. Cytogenet
Genome Res 100:252–260
Brent GA (2008) Clinical practice. Graves’ disease. N Engl J Med 358:2594–2605
Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I (1993) Serum anti-GQ1b IgG antibody
is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome:
clinical and immunohistochemical studies. Neurology 43:1911–1917
Croquet M, Vallat JM, Vital C, Fournier M, Barat M, Orgogozo JM, Julien J, Loiseau P (1983)
Nuclear inclusions in oculopharyngeal dystrophy. An ultrastructural study of six cases. J Neurol
Sci 60:151–156
Drachman DB (1994) Myasthenia gravis. N Engl J Med 330:1797–1810
Drachman DB (2008) Therapy of myasthenia gravis. Handb Clin Neurol 91:253–272
Drachman DB, Adams RN, Hu R, Jones RJ et al (2008) Rebooting the immune system with highdose
cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci
1132:305–314
Dupuis L, Loef fl er JP (2009) Neuromuscular junction destruction during amyotrophic lateral sclerosis:
insights from transgenic models. Curr Opin Pharmacol 9:1–6
Dupuis L, Gonzalez de Aguilar JL, Echaniz-Laguna A, Eschbach J et al (2009) Muscle mitochondrial
uncoupling dismantles neuromuscular junction and triggers distal degeneration of motor
neurons. PLoS One 4:e5390
Dupuis L, Pradat PF, Ludolph AC, Loef fl er JP (2011) Energy metabolism in amyotrophic lateral
sclerosis. Lancet Neurol 10:75–82
Eckstein AK, Plicht M, Lax H, Neuhäuser M et al (2006) Thyrotropin receptor autoantibodies are
independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome
of the disease. J Clin Endocrinol Metab 91:3463–3470
Elliott HR, Samuels DC, Eden JA, Relton CL, Chinnery PF (2008) Pathogenic mitochondrial
DNA mutations are common in the general population. Am J Hum Genet 83:254–260
Elrod RD, Weinberg DA (2004) Ocular myasthenia gravis. Ophthalmol Clin North Am
17:275–309
Emery AE (2002) The muscular dystrophies. Lancet 359:687–695
Ervasti JM, Sonnemann KJ (2008) Biology of the striated muscle dystrophin-glycoprotein complex.
Int Rev Cytol 265:191–225
Fischer RL, Culver DG, Tennant P et al (2004) Amyotrophic lateral sclerosis is a distal neuropathy:
evidence in mice and man. Exp Neurol 185:232–240